What China’s Latest Drug Negotiations Mean for Global Pharma Companies

Posted by Crystal Lam on Wed, Jan 22, 2020

Sonia Yan and Daniel Blessing co-authored this blog post with Crystal Lam.

China’s National Healthcare Security Administration (NHSA) recently released the outcomes of its 2019 National Reimbursed Drug List (NRDL) negotiations: 70 of 119 new therapies were successfully listed. This record outcome more than doubled the number of therapies reimbursed through China’s negotiation pathway, which was formally implemented in 2017.


>
Read More

How Cloud Tech Has Leveled the Pharma Field

Posted by Kapil Nayyar on Thu, Aug 23, 2018

A new business entering the competitive pharmaceuticals market faces a steep climb, so any innovation capable of creating a handhold is highly valuable. The evolution of cloud computing technology over the past decade has been a particularly favorable development for startups, offering them essential resources and capabilities that might otherwise be cost prohibitive. At a high level, cloud tech encompasses several benefits:


>
Read More

Get More Out of Your Next Strategy Workshop

Posted by Jennifer Curtis on Mon, Apr 23, 2018

Malik Kaman co-wrote this blog post with Jennifer Curtis. 

Strategy workshops help organizations explore how their actions can drive market events and competitor responses. They’re an internal exercise for the organization to prepare, debate and challenge internal assumptions and to assess strategic choices. When executed effectively, the workshop will challenge participants to define clear strategic objectives, inspire lively debate and encourage the critical evaluation of a diverse list of ideas.


>
Read More

AI Will Usher in ‘Dramatic’ Changes to Pharma’s Commercial Model

Posted by Pratap Khedkar on Thu, Jan 18, 2018

This is the second post in a three-part series on artificial intelligence in healthcare. 

Artificial intelligence is poised to revolutionize the healthcare ecosystem. Providers are starting to apply AI in an effort to leverage patient data, therapy information and standards of care to make better treatment decisions. Payers are experimenting with AI to help with pre-authorization and claims adjudication. Whether or not the pharma industry is ready, AI is changing the way that pharma’s customers and stakeholders do business, thereby necessitating changes to pharma’s own commercial practices. And, according to my colleague John Piccone, those changes will be “dramatic.”


>
Read More

Is AI in Pharma Ready to Move From Hype to Hope?

Posted by Pratap Khedkar on Thu, Jan 11, 2018

This is the first post in a three-part series on artificial intelligence in healthcare. 

We encounter artificial intelligence platforms outside of healthcare on a regular basis, like when we ask Siri a question or view Netflix’s list of suggested films. However, within healthcare, and in the pharmaceutical industry specifically, AI has yet to live up to that level of success. In the near future, will AI become embedded in pharma R&D? Will it enable treatment decisions to be more automated—and more accurate? I recently called my colleague John Piccone, a ZS principal and advanced data science expert who previously led IBM Watson Health’s life sciences offerings, to discuss AI’s use both within pharma and throughout the healthcare ecosystem.


>
Read More